Loading data for MYGN — first visit, this takes a few seconds.
Myriad Genetics, Inc. (MYGN)
NasdaqGS: MYGN
· Real-Time Price · USD
3.42
+0.06 (1.79%)
At close: Sep 11, 2026, 3:59 PM
3.43
+0.29%
After-hours: 7:50 PM
The price, the headline numbers and the latest news, in one place.
Myriad Genetics, Inc. (MYGN) Stock Price, Analysis & Data
1.79% (1D)
| Bid | 2.41 |
| Market Cap | 327M |
| Revenue (ttm) | 557M |
| Net Income (ttm) | -230M |
| 1.64 | |
| -1.18 | |
| n/a | |
| -5.97 | |
| P/B (ttm) | 1.08 |
| P/S (ttm) | 0.59 |
| Earnings Date | Nov 3, 2025 |
| Ask | 4.1 |
| Volume | 2,550,526 |
| Avg. Volume (20D) | 1,863,882 |
| Open | 3.37 |
| Previous Close | 3.36 |
| Day's Range | 3.19 - 3.42 |
| 52-Week Range | 2.74 - 8.59 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About MYGN
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate...
Industry Diagnostics & Research
Sector Healthcare
IPO Date Oct 6, 1995
Employees 2,700
Stock Exchange NasdaqGS
Ticker Symbol MYGN
Website https://www.myriad.com
Financial Performance
In 2025, Myriad Genetics's revenue was 824.5M, a decrease of -1.56% compared to the previous year's 837.6M. Earnings were -365.9M, an increase of 187.43%.
Financial StatementsEarnings Surprise
Myriad Genetics has released their quarterly earnings on Jul 30, 2026:
- Revenue of n/a misses estimates by $0, with -100.00% YoY decline.
- EPS of -0.25 misses estimates by -0.19, with -733.33% YoY decline.
Myriad Genetics, Inc. is scheduled to release its earnings on Nov 3, 2025, after market closes.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade



